Teva- Pharmaceutical Industries Profit Margin

Teva- Pharmaceutical Industries posts a profit margin of 2.94% as of September 2026. That compares with 4.24% in the prior-year period — down 30.8% year over year. That is below the Healthcare sector average of 19.13%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Teva- Pharmaceutical Industries's profit margin was 4.24%. The latest reading is 2.94% — a 30.8% year-over-year decrease (period ending September 2026). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 19.13% is typical. Teva- Pharmaceutical Industries's 2.94% is lower that level. That is roughly 84.6% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Teva- Pharmaceutical Industries's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 2.94% as of September 2026; use YoY and peer views to separate noise from signal.

Context for TEVA's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 19.13%), and (3) consistency with growth and profitability. This page covers the first two; Teva- Pharmaceutical Industries's other metric pages and overview cover the third.